Time‐course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis
暂无分享,去创建一个
N. Hotta | K. Matsuura | A. Morishita | J. Tani | A. Tsubota | T. Ishikawa | Yasuhito Tanaka | K. Iwakiri | H. Toyoda | M. Nakamuta | M. Iwasa | T. Kumada | A. Hiraoka | S. Fukunishi | Tsunamasa Watanabe | T. Shima | A. Nozaki | M. Chuma | Y. Tachi | T. Tada | S. Mikami | K. Takaguchi | N. Shimada | M. Atsukawa | Keizo Kato | I. Hidaka | T. Akahane | H. Abe | H. Uojima | T. Asano | T. Okubo | C. Kondo | K. Tsuji | K. Kawata | Akio Moriya | S. Fujioka | H. Okubo | K. Morita | C. Ogawa | T. Arai | M. Kitamura | Yoshihiko Tachi
[1] M. Kurosaki,et al. Real‐world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1‐ and 2‐infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group , 2021, Journal of medical virology.
[2] K. Matsuura,et al. Characteristics and Prognosis of De Novo Hepatocellular Carcinoma After Sustained Virologic Response , 2021, Hepatology communications.
[3] Yoshiyuki Suzuki,et al. Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study , 2021, BMC Gastroenterology.
[4] K. Chayama,et al. Comparison of the Prognosis of Decompensated Cirrhosis in Patients with and Without Eradication of Hepatitis C Virus , 2021, Infectious Diseases and Therapy.
[5] Y. Shibasaki,et al. Real‐world hospital mortality of liver cirrhosis inpatients in Japan: a large‐scale cohort study using a medical claims database , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.
[6] K. Iwakiri,et al. Development of interferon-free, direct-acting antivirals treatment for Japanese patients with chronic hepatitis C infection and chronic kidney disease. , 2021, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.
[7] Kouichi Miura,et al. Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.
[8] H. Yoshiji,et al. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study , 2020, Journal of Gastroenterology.
[9] M. Imamura,et al. Real‐world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus‐related decompensated cirrhosis , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.
[10] N. Hotta,et al. Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study , 2020, Infectious Diseases and Therapy.
[11] A. Tanaka. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update , 2020, Hepatology research : the official journal of the Japan Society of Hepatology.
[12] N. Hotta,et al. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study , 2020, Hepatology International.
[13] S. Asch,et al. Long‐Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents , 2020, Hepatology.
[14] Y. Takei,et al. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema , 2019, Journal of gastroenterology and hepatology.
[15] M. Nakao,et al. Involvement of portosystemic shunts in impaired improvement of liver function after direct‐acting antiviral therapies in cirrhotic patients with hepatitis C virus , 2019, Hepatology research : the official journal of the Japan Society of Hepatology.
[16] J. Mar,et al. Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments , 2019, Expert review of gastroenterology & hepatology.
[17] N. Hotta,et al. The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study , 2019, Alimentary pharmacology & therapeutics.
[18] A. Tsubota,et al. Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan , 2019, Open forum infectious diseases.
[19] G. Ioannou,et al. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection? , 2019, Gastroenterology.
[20] Giovanni Raimondo,et al. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. , 2018, Gastroenterology.
[21] M. Manns,et al. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection. , 2018, Gastroenterology.
[22] M. Kudo,et al. Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function , 2017, Liver Cancer.
[23] A. Walker,et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.
[24] A. Walker,et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.
[25] M. Kumar,et al. APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing , 2016, Hepatology International.
[26] K. Reddy,et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. , 2015, The New England journal of medicine.
[27] M. Pedrosa,et al. Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score From a National Electronic Healthcare Database. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[28] H. Wedemeyer,et al. Improvement of liver function parameters in advanced HCV‐associated liver cirrhosis by IFN‐free antiviral therapies , 2015, Alimentary pharmacology & therapeutics.
[29] Aasld Idsa Hcv Guidance Panel. Hepatitis C guidance: AASLD‐IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus , 2015, Hepatology.
[30] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[31] G. D’Amico,et al. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. , 2006, Journal of hepatology.